BGP 15

Drug Profile

BGP 15

Alternative Names: BGP-15

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator N-Gene Research Laboratories
  • Developer Allos Therapeutics; N-Gene Research Laboratories; University of Melbourne
  • Class Antihyperglycaemics; Oximes; Piperidines; Small molecules
  • Mechanism of Action HSP70 heat shock protein stimulants; JNK mitogen-activated protein kinase inhibitors; Oxygen radical formation antagonists; Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes - Duchenne muscular dystrophy

Highest Development Phases

  • Phase II Insulin resistance; Type 2 diabetes mellitus
  • No development reported Duchenne muscular dystrophy
  • Discontinued Chemotherapy-induced damage; Reperfusion injury

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in Australia
  • 20 Aug 2015 BPG 15 is still in phase-II development for Insulin resistance and Type-2 diabetes mellitus in Hungary and USA
  • 20 Aug 2013 BGP 15 is available for licensing as of 19 Apr 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top